Merck and Pfizer Collaborate to Develop New SGLT2 Drug, Ertugliflozin

There is currently fierce competition to get SGLT2 medications approved and onto the market. The first SGLT2 drug, Invokana (canagliflozin), developed by Johnson and Johnson, was approved by the FDA just recently. Ertugliflozin, which is ready for Phase III trials, will likely be marketed as a drug taken on its own as a fixed-dose, or in combination with metformin and Januvia (sitagliptin), both oral antihyperglycemic agents….